انتقل إلى وضع عدم الاتصال باستخدام تطبيق Player FM !
5-Minute Check In: Evaluating the Use of Resmetirom in Patients with NASH and Liver Fibrosis
Manage episode 418455867 series 3291352
First-of-its-kind medication shows promise for liver disease patients
- Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), is estimated to affect nearly one-quarter of adults in the United States. Nonalcoholic steatohepatitis (NASH) is a form of MASLD that can cause liver fibrosis, cirrhosis, liver failure, and liver cancer. It is one of the most common reasons why patients need liver transplants.
- The FDA recently granted accelerated approval to resmetirom, the first medication to treat nonalcoholic steatohepatitis (NASH) and liver fibrosis.
- Prior to the FDA approval, there were no approved drugs to treat this disease
In this 5-minute check in, we review the promising phase 3 data from a randomized trial that led to FDA approval including the results, the implications for patient care, and the potential to transform the landscape of NASH management
Guest: Dr. Justin Reynolds, Associate Professor, Creighton University School of Medicine, Gastroenterologist and Transplant Hepatologist, St Joseph's Hospital and Medical Center Transplant Center in Phoenix, Arizona.
105 حلقات
5-Minute Check In: Evaluating the Use of Resmetirom in Patients with NASH and Liver Fibrosis
5-Minute Clinical Update and Grand Rounds with Dr. Thomas McGinn
Manage episode 418455867 series 3291352
First-of-its-kind medication shows promise for liver disease patients
- Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), is estimated to affect nearly one-quarter of adults in the United States. Nonalcoholic steatohepatitis (NASH) is a form of MASLD that can cause liver fibrosis, cirrhosis, liver failure, and liver cancer. It is one of the most common reasons why patients need liver transplants.
- The FDA recently granted accelerated approval to resmetirom, the first medication to treat nonalcoholic steatohepatitis (NASH) and liver fibrosis.
- Prior to the FDA approval, there were no approved drugs to treat this disease
In this 5-minute check in, we review the promising phase 3 data from a randomized trial that led to FDA approval including the results, the implications for patient care, and the potential to transform the landscape of NASH management
Guest: Dr. Justin Reynolds, Associate Professor, Creighton University School of Medicine, Gastroenterologist and Transplant Hepatologist, St Joseph's Hospital and Medical Center Transplant Center in Phoenix, Arizona.
105 حلقات
Усі епізоди
×مرحبًا بك في مشغل أف ام!
يقوم برنامج مشغل أف أم بمسح الويب للحصول على بودكاست عالية الجودة لتستمتع بها الآن. إنه أفضل تطبيق بودكاست ويعمل على أجهزة اندرويد والأيفون والويب. قم بالتسجيل لمزامنة الاشتراكات عبر الأجهزة.